|
T2043 |
Mutant IDH1-IN-1
|
IDH1-IN-1 |
Dehydrogenase
,
Isocitrate Dehydrogenase (IDH)
|
|
Mutant IDH1-IN-1 is a potent mutant IDH1 R132 h inhibitor with IC50 < 0.1 uM. |
|
T16161 |
Mutant IDH1 inhibitor
|
|
Dehydrogenase
,
Isocitrate Dehydrogenase (IDH)
|
|
Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM). |
|
T12128 |
Mutant IDH1-IN-2
|
|
Isocitrate Dehydrogenase (IDH)
|
|
Mutant IDH1-IN-2 is a mutant Isocitrate dehydrogenase (IDH) proteins inhibitor |
|
T39716 |
Mutant IDH1-IN-6
|
Mutant IDH1-IN-6 |
|
|
Mutant IDH1-IN-6 is an orally active compound that effectively inhibits mutant isocitrate dehydrogenase (IDH) enzymes. It demonstrates potency and selectivity, with IC50 values of 6.27, 3.71, 36.9, and 11.5 nM for IDH1 R... |
|
T11612 |
IDH1 Inhibitor 3
|
|
Others
|
|
IDH1 Inhibitor 3 is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor (IC50: 45 nM for IDH1R132H). |
|
T11611 |
IDH1 Inhibitor 2
|
|
Dehydrogenase
|
|
IDH1 Inhibitor 2 (compound 13) is a potent IDH1 inhibitor via direct covalent modification of His315 (IC50: 110 nM). |
|
T11613 |
IDH1 Inhibitor 1
|
|
Others
|
|
IDH1 Inhibitor 1 is an orally bioavailable, brain-penetrant, and selective mutant IDH1 inhibitor (IC50s: 0.021 μM, 0.045 μM, and 2.52 μM for IDH1R132H, IDH1R132C, and IDH1WT). |
|
T12129 |
Mutant IDH1-IN-4
|
|
Others
|
|
Mutant IDH1-IN-4 is an mutant Isocitrate dehydrogenase 1 (IDH 1) inhibitor. |
|
T78758 |
IHMT-IDH1-053
|
|
Isocitrate Dehydrogenase (IDH)
|
|
IHMT-IDH1-053 (compound 16) is an irreversible inhibitor exhibiting high selectivity for the IDH1 R132H mutant, achieving an IC50 of 4.7 nM. It preferentially targets IDH1 mutants over wild-type IDH1 and IDH2, both wild-... |
|
T62725 |
IDH1 Inhibitor 5
|
|
|
|
IDH1 Inhibitor 5 (compound 2) is an inhibitor of IDH1 (isocitrate dehydrogenase 1), which inhibits MOG cells (IC50: 64.4 nM) and wild-type IDH1 glioma cells expressing exogenous mutant IDH1 R132H protein (IC50: 34.9 nM). |
|
T72705 |
IDH1 Inhibitor 7
|
|
|
|
IDH1 Inhibitor 7 is an IDH1 inhibitor with an IC 50 of less than 100 nM . |
|
T63403 |
WT IDH1 Inhibitor 2
|
|
|
|
WT IDH1 Inhibitor 2 is a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor (IC50: 120 nM) and is a mutant R132H IDH1 inhibitor, an isoform of GSK321 with wild-type cross-reactivity. |
|
T63402 |
(S,R)-WT IDH1 Inhibitor 2
|
|
|
|
(S,R)-WT IDH1 Inhibitor 2 is a selective and potent mutant IDH1 inhibitor that inhibits R132G (IC50: 2.9 nM), R132C (IC50: 3.8 nM), R132H (IC50: 4.6 nM) and WT IDH1 (IC50: 46 nM) with 100-fold higher selectivity than IDH... |
|
T6820 |
D-α-Hydroxyglutaric acid disodium
|
D-alpha-Hydroxyglutaric acid disodium salt,Disodium (R)-2-Hydroxyglutarate |
ATPase
,
Others
,
Reactive Oxygen Species
,
Endogenous Metabolite
,
mTOR
|
|
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-Hydroxyglutarate) is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases with Ki of 0.628 mM. |
|
T62698 |
MIDH1-IN-1
|
|
|
|
mIDH1-IN-1 (compound 43) is a potent and selective inhibitor of mIDH1 (isocitrate dehydrogenase 1 mutant) (IC50: 961.5 nM). mIDH1-IN-1 effectively inhibits the production of 2-HG (2-hydroxyglutarate) in HT1080 cells (EC5... |
|
T15550 |
IDH-305
|
|
Dehydrogenase
|
|
IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor. IDH-305 shows greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50s: 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (... |
|
T15551 |
IDH889
|
|
Dehydrogenase
|
|
IDH889 is a brain penetrant, an allosteric and mutant specific IDH1 inhibitor. IDH889 has effective selectivity for IDH1 R132* mutations (IC50s: 0.02 μM, 0.072 μM, and 1.38 μM for IDH1R132H, IDH1R132C, and IDH1wt). |
|
T16384 |
Olutasidenib
|
FT-2102 |
Dehydrogenase
,
Isocitrate Dehydrogenase (IDH)
|
|
Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Iso... |
|
T3617 |
Ivosidenib
|
AG-120 |
Dehydrogenase
,
Isocitrate Dehydrogenase (IDH)
|
|
Ivosidenib (AG-120) is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhi... |
|
T2104 |
AGI-5198
|
IDH-C35 |
Dehydrogenase
,
Isocitrate Dehydrogenase (IDH)
|
|
AGI-5198 (IDH-C35) is a highly effective and specific inhibitor of IDH1 R132H/R132C mutants (IC50: 0.07/0.16 μM). |
|
TQ0042 |
BAY-1436032
|
|
Dehydrogenase
,
Isocitrate Dehydrogenase (IDH)
|
|
BAY-1436032 is a novel, selective and orally available inhibitor of pan-mutant isocitrate dehydrogenase 1 (IDH1). |
|
T22253 |
AG-120 (racemic)
|
|
Dehydrogenase
|
|
AG-120 (racemic), the racemic mixture of AG-120, is an orally available isocitrate dehydrogenase type 1 (IDH1) inhibitor, and shows potential antineoplastic activity. |
|
T15442 |
GSK864
|
|
Others
|
|
GSK864 is an inhibitor of isocitrate dehydrogenase 1 (IDH1) mutant. GSK864 inhibits IDH1 mutants R132C, R132H, and R132G (IC50: 8.8, 15.2, and 16.6 nM). |
|
T63778 |
Safusidenib
|
|
|
|
Safusidenib is a selective, orally active mutant inhibitor of IDH1 that significantly inhibits mutant IDH1, but not wild-type IDH1, and inhibits tumor activity in chondrosarcoma. safusidenib is active against IDH1R132H a... |
|
T32013 |
GSK990
|
GSK-990,GSK 990 |
|
|
GSK990 is similar to GSK864 but is inactive as an IDH1 inhibitor, may be used as a native control to GSK864. |
|
T7307 |
Vorasidenib
|
PVM/MA,AG-881 |
Isocitrate Dehydrogenase (IDH)
|
|
Vorasidenib (PVM/MA) is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC50s = 31.9 and 31.7 nM for IDH1R132H and IDH2R140Q, respectively) |
|
T26898 |
BRD2879
|
BRD 2879,BRD-2879 |
|
|
BRD2879 is a potent and cell-active inhibitor of IDH1-R132H (IC50 = 50 nM). |
|
T32009 |
GSK321
|
GSK 321,GSK-321 |
|
|
GSK321 is an effective and selective IDH1 mutation inhibitor, which can effectively inhibit the production of 2-HG in HT-1080 cells, and induce IDH1 mutant cells to differentiate into bone marrow at the level of leukemia... |
|
T38004 |
ML-309 (hydrochloride)
|
|
|
|
ML-309 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). It reversibly and selective inhibits IDH1R132H over wild-type IDH1 (IC50s = 96 and 36,500 nM, respectively). ML-309 reduces 2-hydroxyglutarate productio... |
|
T70890 |
ML309
|
|
|
|
ML309 is a potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. ML309 is capable of potent and selective inhibition of mutant IDH1 and effectively lowers c... |
|
T25006 |
AGI-14100
|
AGI 14100 |
Dehydrogenase
|
|
AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia. |
